Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2558133 | 0.88 | HSD17B10 (0.66) | HSD17B10AKR1C3AKR1C2PTGS1KDM4E | |
| SCHEMBL21464140 | 0.87 | HSD17B10 (0.51) | HSD17B10AKR1C3AKR1C2KDM4ESMN1; SMN2 | |
| SCHEMBL1399960 | 0.86 | HSD17B10 (0.63) | HSD17B10AKR1C3AKR1C2PTGS1KDM4E | |
| SCHEMBL687106 | 0.86 | KDM4E (0.53) | HSD17B10AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL8478030 | 0.84 | SMN1; SMN2 (0.56) | HSD17B10AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL8478029 | 0.84 | KDM4E (0.51) | HSD17B10AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL11307860 | 0.84 | HSD17B10 (0.60) | HSD17B10AKR1C3AKR1C2PTGS1KDM4E | |
| SCHEMBL25386128 | 0.83 | PPARG (0.48) | HSD17B10AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL2317055 | 0.83 | AKR1C3 (0.50) | HSD17B10AKR1C3AKR1C2KDM4EPOLB | |
| Alcohol SCHEMBL28006228 | 0.83 | SMN1; SMN2 (0.54) | HSD17B10AKR1C3AKR1C2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360219-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12239711-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-118480030-A | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-112262134-B | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230082997-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20220227729-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-21 | — | — | US | disclosed |
| EP-3972963-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3774772-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112262134-A | Cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| WO-2020234103-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | WO | disclosed |
| EP-1906945-A2 | HCV INHIBITORS | Virobay, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1745024-A4 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070249665-A1 | 1-aryl-4-substituted isoquinolines | NEUROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| EP-1745024-A1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2005110991-A1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360219-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | HSD17B10 3818/4885AKR1C3 3071/4885AKR1C2 3245/4885 |
| US-12239711-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | HSD17B10 3818/4885AKR1C3 3071/4885AKR1C2 3245/4885 |
| US-20220227729-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | KRAS, NRAS, BRCA1 | HSD17B10 4386/4885AKR1C3 1210/4885AKR1C2 1227/4885 |
| US-20070249665-A1 | 1-aryl-4-substituted isoquinolines | C3AR1, C5AR1, C5AR2 | HSD17B10 4180/4885AKR1C3 199/4885AKR1C2 785/4885 |
| US-20230082997-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | HSD17B10 3818/4885AKR1C3 3071/4885AKR1C2 3245/4885 |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | HAVCR2, EIF2AK2, GTF3C1 | HSD17B10 2537/4885AKR1C3 1064/4885AKR1C2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.